Relay Therapeutics, Inc.
RLAY
$3.69
$0.288.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -76.27% | -78.26% | -60.83% | -61.22% | 3,637.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.27% | -78.26% | -60.83% | -61.22% | 3,637.58% |
| Cost of Revenue | -16.20% | -5.86% | -3.35% | 2.66% | 9.24% |
| Gross Profit | 9.02% | -2.94% | -1.53% | -8.33% | 2.12% |
| SG&A Expenses | -7.65% | 0.48% | 2.11% | 2.80% | 4.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.55% | -4.63% | -2.29% | 2.69% | 8.27% |
| Operating Income | 8.73% | -2.41% | -1.65% | -7.16% | 0.81% |
| Income Before Tax | 3.49% | -1.30% | 1.25% | -5.90% | 6.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.49% | -1.30% | 1.25% | -5.90% | 6.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.49% | -1.30% | 1.25% | -5.90% | 6.27% |
| EBIT | 8.73% | -2.41% | -1.65% | -7.16% | 0.81% |
| EBITDA | 8.70% | -2.50% | -1.62% | -7.14% | 1.03% |
| EPS Basic | 22.77% | 15.40% | 14.13% | 2.54% | 13.08% |
| Normalized Basic EPS | 26.95% | 14.06% | 12.21% | 2.68% | 11.30% |
| EPS Diluted | 22.77% | 15.40% | 14.13% | 2.54% | 13.08% |
| Normalized Diluted EPS | 26.95% | 14.06% | 12.21% | 2.68% | 11.30% |
| Average Basic Shares Outstanding | 26.91% | 22.04% | 16.58% | 8.73% | 7.53% |
| Average Diluted Shares Outstanding | 26.91% | 22.04% | 16.58% | 8.73% | 7.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |